Abdominal visceral fat accumulation is associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 8, 2007, Pages 1189-1197

  Anan, Futoshi ^a,b   Masaki, Takayuki ^b   Yonemochi, Hidetoshi ^b   Takahashi, Naohiko ^b   Nakagawa, Mikiko ^b   Eshima, Nobuoki ^c   Saikawa, Tetsunori ^b   Yoshimatsu, Hironobu ^b  

^a OITA RED CROSS HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

123I metaiodobenzylguanidine scintigraphy; Cardiac autonomic function; Insulin resistance; Type 2 diabetes; Visceral fat accumulation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; INSULIN; NORADRENALIN;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC PATIENT; DRUG UPTAKE; FEMALE; HEART FUNCTION; HEART RATE VARIABILITY; HEART SCINTISCANNING; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PRESSORECEPTOR REFLEX;

3-IODOBENZYLGUANIDINE; ADIPOSE TISSUE; AGED; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INSULIN RESISTANCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 34548100044     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0421-6     Document Type: Article

References (48)

1. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-20.
2. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10:497-511.
3. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000;23:465-71.
4. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, et al. Visceral adiposity and the prevalence of hypertension in Japanese-Americans. Circulation 2003;108:1718-23.
5. Fujimoto W, Bergstrom R, Boyko E, Chen K, Leonetti D, Newell-Morris L, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men: the 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999;22:1808-12.
6. St-Pierre J, Lemieux I, Vohl MC, Perron P, Tremblay G, Despres JP, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 2002;90:15-8.
7. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001;86:5366-71.
8. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002;87:5098-103.
9. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Study. Circulation 1996;94:2850-5.
10. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infraction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infraction) Investigators. Lancet 1998;351:478-84.
11. Takahashi N, Nakagawa M, Saikawa T, Ooie T, Yufu K, Shigematsu S, et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232-7.
12. Anan F, Takahashi N, Nakagawa M, Ooie T, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005;54:552-8.
13. 123I- metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients. Eur J Nucl Med Mol Imaging 2007;34:28-35.
14. Gerritsen J, TenVoorde BJ, Dekker JM, Kingma R, Kostense PJ, Bouter LM, et al. Measures of cardiovascular autonomic dysfunction nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia 2003;46:330-8.
15. 123I-MIBG. J Nucl Med 1999;40:6-11.
16. Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997;46:S67-76.
17. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999;17:1161-8.
18. Matsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997;13:313.
19. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998;21:2116-22.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
21. Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211:283-6.
22. 40K. Int J Obes 1988;12:249-66.
23. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'Obesity Disease' in Japan. Circ J 2002;66:987-92.
24. Sato T, Nishinaga M, Kawamoto A, Ozawa T, Takatsuji H. Accuracy of a continuous blood pressure monitor based on arterial tonometry. Hypertension 1993;21:866-74.
25. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabete Metab Res Rev 2002;18:S5-9.
26. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, et al. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 2000;49:2116-25.
27. Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger M. Plasma levels of tumor necrosis factor-alpha (TNF-α) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes Metab 2000;26:178-82.
28. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:859-62.
29. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-233.
30. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endcrinol Metab 2001;86:1930-5.
31. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002;87:2407.
32. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin kinks obesity to diabetes. Nature 2001;409:307-12.
33. Lindmark S, Wiklund U, Olsson T, Eriksson JW. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 2005;13:717-28.
34. Beske SD, Alvarez GE, Ballard TP, Davy KP. Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 2002;282:H630-5.
35. Kinjyo Y, Kajiyama S, Fujiwara H, Kanegawa N, Saji H. Influence of the polyol pathway on transporter reduction in diabetic cardiac sympathetic nerve: implication for heterogeneous accumulation of MIBG. Eur J Nucl Med Imaging 2005;32:438-42.
36. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34:1140-6.
37. 123I] metaiodobenzylguanidine. Diabetes 1992;41:1069-75.
38. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidant stress: protective effect of vitamin C. Diabetes 2001;50:159-65.
39. Meigs J, Jacques P, Selhub J, Singer D, Nathan D, Rifai N, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring study. Diabetes Care 2001;24:1403-10.
40. Taegher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-8.
41. Borden G. Free fatty acids and insulin secretion in humans. Curr Diab Rep 2005;5:167-70.
42. Benthem L, Keizer K, Wiegman CH, de Boer SE, Strubbe JH, Steffens AB, et al. Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation. Am J Physiol Endocrinol Metab 2000;279:E1286-93.
43. Morricone L, Malavazos AE, Coman C, Donati C, Hassan T, Caviezel F. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 2002;10:489-98.
44. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001;14 (Pt 2):231S-6S.
45. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298-303.
46. Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-61.
47. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm 2001;58:671-83.
48. Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 2004;31:1353-5.